Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Pulls EPS Guidance To Avoid "Indiscriminate Short-Term Cost Cutting"

This article was originally published in The Pink Sheet Daily

Executive Summary

In Kenneth Frazier's first financial call as CEO, the exec withdrew Merck's long-term earnings guidance, citing healthcare reform costs, European pricing pressure and a late-stage pipeline setback.

You may also be interested in...



Business and Finance News, In Brief

Oral Treprostinil Meets Phase III Endpoint

Business and Finance News, In Brief

Oral Treprostinil Meets Phase III Endpoint

For Pfizer Chief, The First Order Of Business Is Research

In Read's first presentation to investors, the new chief executive laid out plans to reorganize research as part of a strategy to improve productivity and cut spending by $1.5 billion in 2012.

Topics

Latest News
UsernamePublicRestriction

Register

PS071901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel